Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.42 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.42 |
| ▸ | NEK2 | P51955 | 2/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.42 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.42 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.42 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411392 | 0.89 | BRAF (0.48) | BRAFPTGER1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL17854927 | 0.88 | BRAF (0.52) | BRAFCYP2C9CYP2C19MAP2K1RIPK2 | |
| SCHEMBL12028662 | 0.85 | BRAF (0.48) | BRAFCYP2C9CYP2C19MAP2K1RIPK2 | |
| SCHEMBL8248243 | 0.84 | BRAF (0.50) | BRAFCYP2C19MAP2K1KDRNEK2 | |
| SCHEMBL412855 | 0.84 | BRAF (0.53) | BRAFCYP2C19MAP2K1RIPK2RAF1 | |
| SCHEMBL411342 | 0.83 | BRAF (0.53) | BRAFCYP2C9CYP2C19MAP2K1RIPK2 | |
| SCHEMBL859122 | 0.82 | BRAF (0.56) | BRAFCYP2C9CYP2C19MAP2K1RIPK2 | |
| SCHEMBL410804 | 0.82 | BRAF (0.52) | BRAFCYP2C9MAP2K1RIPK2RAF1 | |
| SCHEMBL1053508 | 0.81 | FABP3 (0.43) | BRAFPTGER1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL416210 | 0.81 | FABP3 (0.42) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194666-A1 | Combination Treatment Methods | MEDICAL RESEARCH COUNCIL (GB) | 2008-08-14 | — | — | US | claimed |
| WO-2006106311-A2 | COMBINATION TREATMENT METHODS FOR TREATING SEX-HORMONE DEPENDENT DISEASE AND FERTILITY TREATMENT | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2006-10-12 | — | — | WO | claimed |
| US-20060171945-A1 | Ip receptor antagonists for the treatment of pathological uterine conditions | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH, THE (GB) | 2006-08-03 | — | — | US | claimed |
| EP-1596858-A1 | IP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PATHOLOGICAL UTERINE CONDITIONS | Medical Research Council (GB) | 2005-11-23 | — | — | EP | claimed |
| WO-2004071508-A1 | IP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PATHOLOGICAL UTERINE CONDITIONS | MEDICAL RESEARCH COUNCIL (GB) | 2004-08-26 | — | — | WO | claimed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3088400-A1 | PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC. (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| EP-1893612-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006106311-A2 | COMBINATION TREATMENT METHODS FOR TREATING SEX-HORMONE DEPENDENT DISEASE AND FERTILITY TREATMENT | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2006-10-12 | — | — | WO | disclosed |
| US-20060171945-A1 | Ip receptor antagonists for the treatment of pathological uterine conditions | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH, THE (GB) | 2006-08-03 | — | — | US | disclosed |
| EP-1596858-A1 | IP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PATHOLOGICAL UTERINE CONDITIONS | Medical Research Council (GB) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004071508-A1 | IP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PATHOLOGICAL UTERINE CONDITIONS | MEDICAL RESEARCH COUNCIL (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885PTGER1 2394/4885CYP2C9 4746/4885 |
| US-20080194666-A1 | Combination Treatment Methods | GNRHR, SHBG, FSHR | BRAF 4797/4885PTGER1 9/4885CYP2C9 2309/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885PTGER1 2394/4885CYP2C9 4746/4885 |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885PTGER1 2394/4885CYP2C9 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.